BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a ...

Lantern Pharma (NasdaqCM:LTRN) Update Summary Company Overview - **Company**: Lantern Pharma - **Drug**: LP-184 - **Focus**: Treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies Key Points Industry and Drug Development - LP-184 is primarily aimed at treating advanced solid tumors, including triple-negative breast cancer (TNBC), glioblastoma (GBM), and bladder cancer, which often exhibit deficiencies in DNA damage repair pathways [2][3] - The drug has completed Phase IA trials with promising safety and tolerability data, showing significant clinical activity across various solid tumor types [3][25] - Lantern Pharma has received three orphan drug designations and two fast-track designations for LP-184, indicating strong market potential [3] Mechanism of Action - LP-184 is designed to exploit synthetic lethality, particularly in tumors with high levels of PTGR1, a gene that enhances the drug's efficacy [4][10] - The drug works by causing double-stranded breaks in DNA, which are particularly lethal to tumor cells deficient in DNA repair mechanisms [4][18] - Tumors with mutations in nucleotide excision repair and homologous recombination pathways show heightened sensitivity to LP-184 [13][14] Clinical Trial Results - The Phase IA study demonstrated a favorable safety profile, with most adverse events being grade 1 or 2 and manageable [31] - Out of 63 enrolled patients, 52 were available for tumor response assessment, with 28 patients achieving stable disease, including four with durable responses lasting over six months [34] - Notably, 87.5% of patients had PTGR1 expression levels sufficient for LP-184 activation, supporting the drug's precision medicine approach [41] Future Clinical Development - Planned Phase IB and II trials will focus on advanced monotherapy and combination therapies, particularly in TNBC and non-small cell lung cancer [26][42] - The trials will utilize a Bayesian adaptive design to expedite the process and improve patient outcomes [28] - There is a strong emphasis on biomarker-driven studies to identify patients most likely to benefit from LP-184 [46] Market Potential - The market for LP-184 is considered exceptional, with estimates suggesting that about 20% of cancers harbor DNA damage repair deficiencies, making them potential candidates for treatment [3][4] - The drug's ability to combine with other therapies, such as PARP inhibitors, positions it as a strong contender in the oncology market [54][55] Additional Insights - LP-184 has shown potential in overcoming resistance to existing therapies, including PARP inhibitors, and may also convert "cold" tumors to "hot" tumors for immunotherapy [15][54] - The drug's ability to cross the blood-brain barrier is particularly advantageous for treating brain metastases associated with TNBC [57] Conclusion - Lantern Pharma's LP-184 represents a promising advancement in the treatment of solid tumors with DNA repair deficiencies, supported by strong preclinical and early clinical data. The ongoing trials and strategic focus on precision medicine could significantly impact patient outcomes and market positioning in oncology [60]

Core Viewpoint - Repare Therapeutics has entered into a definitive arrangement agreement with XenoTherapeutics, Inc. for a proposed acquisition, with significant shareholders agreeing to support the transaction [1][2]. Group 1: Transaction Details - The transaction involves XenoTherapeutics acquiring all issued and outstanding common shares of Repare Therapeutics [1]. - Shareholders representing approximately 40% of Repare's common shares have committed to vote in favor of the transaction [2]. Group 2: Company Overview - Repare Therapeutics is a clinical-stage precision oncology company focused on developing targeted cancer therapies through a proprietary synthetic lethality approach [3]. - The company's clinical pipeline includes RP-3467, a Phase 1 Pol ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor [3]. Group 3: Proxy Statement Information - Repare intends to file a proxy statement with the SEC regarding the proposed transaction, which will contain important information for shareholders [4]. - Shareholders will be able to access the proxy statement and other relevant documents for free on the SEC's website or through the company's investor relations [5].

Core Points - Repare Therapeutics has entered into a definitive agreement to be acquired by XenoTherapeutics, with shareholders expected to receive approximately US$1.82 per share plus one contingent value right (CVR) for each common share [1][2][5] - The transaction is anticipated to close in the first quarter of 2026, subject to shareholder and court approvals [6][8] - Repare is actively pursuing additional monetization efforts for its product candidates and intellectual property [3][4] Transaction Details - Each Repare shareholder will receive a cash payment based on the company's cash balance at the time of closing, estimated at US$1.82 per share [2] - Shareholders will also receive a CVR that entitles them to additional cash payments based on future revenues from existing partnerships and potential licensing agreements [3][4] - The transaction requires approval from at least 66% of voting shareholders and a majority excluding certain interested parties [6][7] Financial Results - As of September 30, 2025, Repare reported cash and cash equivalents of $112.6 million, an increase from $109.5 million as of June 30, 2025 [17] - Revenue from collaboration agreements for the three months ended September 30, 2025, was $11.6 million, compared to nil for the same period in 2024 [17] - The company reported a net income of $3.3 million for the three months ended September 30, 2025, compared to a net loss of $34.4 million for the same period in 2024 [17][26] Board and Advisory Recommendations - The Board of Directors unanimously approved the transaction, determining it to be in the best interest of Repare and its stakeholders [5][9] - A transaction committee of independent directors recommended entering into the agreement after thorough evaluation [9] Future Implications - Following the completion of the transaction, Repare will become a privately held company, and its shares will be delisted from the Nasdaq [8] - The company plans to cease being a reporting issuer under Canadian securities laws and deregister its shares under U.S. securities laws [8]

Core Insights - Tango Therapeutics, Inc. is participating in the 2025 Jefferies Global Healthcare Conference with a presentation by CEO Barbara Weber scheduled for November 19, 2025 [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-event [2] - Tango Therapeutics focuses on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]

Core Insights - Tango Therapeutics reported promising clinical data for vopimetostat (TNG462), indicating a median progression-free survival (mPFS) of 7.2 months in patients with second-line MTAP-del pancreatic cancer, supporting the initiation of a pivotal trial in 2026 [1][5] - The company secured $225 million in financing, extending its cash runway into 2028, which will support ongoing clinical studies and development plans [1][2] - The combination studies of vopimetostat with RAS(ON) inhibitors are progressing well, with initial data expected in 2026 [1][2] Clinical Development - Vopimetostat demonstrated a 49% overall response rate (ORR) and a mPFS of 9.1 months in a histology-selective cohort of difficult-to-treat cancers, providing evidence of its strong activity [1][5] - The ongoing combination study of vopimetostat with RAS(ON) inhibitors is well-tolerated, with initial data anticipated in 2026 [5] - TNG456, another candidate, received Orphan Drug Designation (ODD) for malignant glioma, which offers marketing exclusivity and incentives upon regulatory approval [4][5] Financial Performance - As of September 30, 2025, the company reported $152.8 million in cash and equivalents, bolstered by $212 million in net proceeds from a public offering, ensuring operational funding through 2028 [8] - Collaboration revenue increased significantly to $53.8 million for Q3 2025, compared to $11.6 million in Q3 2024, driven by the conclusion of a collaboration agreement with Gilead [9] - The net income for Q3 2025 was $15.9 million, a turnaround from a net loss of $29.2 million in the same period of 2024 [14] Upcoming Milestones - The company plans to initiate a pivotal study for vopimetostat in second-line pancreatic cancer in 2026, alongside updates from ongoing studies [2][6] - Initial safety and efficacy data from the combination trials of vopimetostat with RAS(ON) inhibitors are expected in 2026 [11][12] - The lung cancer cohort of the vopimetostat study is fully enrolled, with updates planned for 2026 [5][11]

Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel cancer therapies using synthetic lethality, targeting genetically-defined tumors [7][8] - The company has a strategic collaboration with Gilead Sciences, Inc. for the development and commercialization of cancer therapies [8][9] - As of October 23, 2025, Tango Therapeutics had a market capitalization of $1.05 billion and a revenue of $24.30 million for the trailing twelve months (TTM) [6] Transaction Summary - Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025, for a total transaction value of approximately $4.85 million [2][3] - Post-transaction, Third Rock Ventures IV, L.P. holds 13,386,574 shares, representing 12.03% of the outstanding shares [3][5] - The sale represented 3.44% of Third Rock Ventures IV, L.P.'s direct ownership as of the transaction date [3] Market Context - The shares were sold at a price of approximately $10.15, which was the weighted average purchase price for the transaction [4] - The stock price had increased nearly 160% in 2025 through October 30, and reached a 52-week high on October 16, 2025 [10][11] Financial Performance - Tango Therapeutics reported a significant decline in revenue in 2025, with Q2 sales of $3.2 million compared to $19.9 million in the same quarter of the previous year [12] - The company experienced an operating loss of $41 million in Q2 2025 [12] Investment Considerations - The sale by Third Rock Ventures is viewed as profit-taking, but the venture capital fund still maintains a significant investment in Tango Therapeutics [10][11] - The current price-to-sales ratio of Tango Therapeutics is 35, indicating that shares may be considered expensive at this time [13]

Core Viewpoint - Tango Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 4, 2025, at 9:00 am ET, prior to the opening of U.S. financial markets, and will not hold a conference call [1] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2]

Core Insights - IDEAYA Biosciences has enrolled its first patient with non-small cell lung cancer (NSCLC) in a Phase 1/2 combination trial of IDE397 and Trodelvy, focusing on patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors [1][2] - The collaboration with Gilead Sciences aims to explore the potential of this combination therapy across multiple solid tumors with MTAP-deletion, an area currently lacking approved targeted therapies [3][4] Company Overview - IDEAYA is a precision medicine oncology company dedicated to developing transformative cancer therapies, utilizing expertise in small-molecule drug discovery and bioinformatics to create targeted therapies aligned with genetic disease drivers [7] - The company has a robust pipeline focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications, aiming to improve clinical outcomes for cancer patients [7] Product Information - Trodelvy is currently approved in over 50 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 40 countries for certain pre-treated HR+/HER2-metastatic breast cancer patients [5] - The use of Trodelvy in MTAP-deletion NSCLC and urothelial cancer (UC) is investigational, with safety and efficacy yet to be established [6]

Core Viewpoint - Tango Therapeutics, Inc. is actively participating in the 2025 Cantor Global Healthcare Conference, highlighting its commitment to engaging with investors and the healthcare community [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3]. - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [3]. - More information about the company can be found on its official website [3]. Event Details - Barbara Weber, M.D., the President and CEO of Tango Therapeutics, will participate in a fireside chat at the conference on September 3, 2025, from 2:45 to 3:15 PM ET [1]. - A live webcast of the event will be available on the company's website, with a replay accessible for 90 days post-presentation [2].